
    
      Topotecan belongs to the most effective medicaments in the therapy of relapsed
      platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3
      or 4 weekly application may be an improvement of therapy. None randomised study exists
      comparing a weekly topotecan application with an application on day 1-5. This study will
      compare the two applications in regard to: rate of complete or partial remissions, rate of
      toxicity, quality of life, progression free survival, overall survival.
    
  